PT1754718E - Factor viii resistente à inactivação - Google Patents
Factor viii resistente à inactivação Download PDFInfo
- Publication number
- PT1754718E PT1754718E PT06004484T PT06004484T PT1754718E PT 1754718 E PT1754718 E PT 1754718E PT 06004484 T PT06004484 T PT 06004484T PT 06004484 T PT06004484 T PT 06004484T PT 1754718 E PT1754718 E PT 1754718E
- Authority
- PT
- Portugal
- Prior art keywords
- acid sequences
- sequences
- proteins
- amino acid
- nucleic acid
- Prior art date
Links
- 229960000301 factor viii Drugs 0.000 title 1
- 230000002779 inactivation Effects 0.000 title 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 abstract 5
- 150000007523 nucleic acids Chemical group 0.000 abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 102000057593 human F8 Human genes 0.000 abstract 3
- 102100026735 Coagulation factor VIII Human genes 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 238000003776 cleavage reaction Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 230000007017 scission Effects 0.000 abstract 2
- 208000031220 Hemophilia Diseases 0.000 abstract 1
- 208000009292 Hemophilia A Diseases 0.000 abstract 1
- 108090000190 Thrombin Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960004072 thrombin Drugs 0.000 abstract 1
- 108010047303 von Willebrand Factor Proteins 0.000 abstract 1
- 102100036537 von Willebrand factor Human genes 0.000 abstract 1
- 229960001134 von willebrand factor Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1611796P | 1996-04-24 | 1996-04-24 | |
| US1778596P | 1996-05-15 | 1996-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1754718E true PT1754718E (pt) | 2011-07-13 |
Family
ID=26688196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT06004484T PT1754718E (pt) | 1996-04-24 | 1997-04-24 | Factor viii resistente à inactivação |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6838437B2 (enExample) |
| EP (3) | EP0910628B1 (enExample) |
| JP (2) | JP3987114B2 (enExample) |
| AT (2) | ATE319817T1 (enExample) |
| AU (1) | AU3202797A (enExample) |
| CA (1) | CA2252896C (enExample) |
| DE (2) | DE69735421T2 (enExample) |
| DK (1) | DK1754718T3 (enExample) |
| PT (1) | PT1754718E (enExample) |
| WO (1) | WO1997040145A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0833848T3 (da) * | 1995-06-12 | 2001-11-05 | Sanquin Bloedvoorziening | Faktor IX-bindende peptider afledt af faktor VIII og anvendelse heraf som inhibitorer af blodkoagulation |
| US8183344B2 (en) | 1996-04-24 | 2012-05-22 | University Of Michigan | Inactivation resistant factor VIII |
| US20040092442A1 (en) * | 1996-04-24 | 2004-05-13 | University Of Michigan | Inactivation resistant factor VIII |
| EP0910628B1 (en) | 1996-04-24 | 2006-03-08 | The Regents of The University of Michigan | Inactivation resistant factor viii |
| AU3289599A (en) * | 1998-02-13 | 1999-08-30 | Cadus Pharmaceutical Corporation | Mekk1 proteins and fragments thereof for use in regulating apoptosis |
| EP1351986A2 (en) * | 2001-01-12 | 2003-10-15 | The American National Red Cross | Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii |
| WO2003100053A1 (en) * | 2002-05-22 | 2003-12-04 | The Children's Hospital Of Philadelphia | Compositions and methods for the treatment of hemophilia a |
| US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
| EP1502921A1 (en) * | 2003-07-29 | 2005-02-02 | ZLB Behring GmbH | Recombinant mutated human factor VIII (FVIII) with improved stability |
| CN101098883B (zh) * | 2004-12-23 | 2013-01-23 | 诺和诺德医疗保健公司 | 减少含有目的维生素k依赖性蛋白质的组合物中的蛋白质污染物的含量 |
| US20110124565A1 (en) * | 2005-04-14 | 2011-05-26 | Hans-Peter Hauser | Modified Coagulation Factor VIII With Enhanced Stability and Its Derivatives |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| US20090203077A1 (en) * | 2006-06-30 | 2009-08-13 | The Regents Of The University Of Michigan | Method of producing factor viii proteins by recombinant methods |
| US20080070251A1 (en) * | 2006-06-30 | 2008-03-20 | Kaufman Randal J | Method of Producing Factor VIII Proteins by Recombinant Methods |
| US8754194B2 (en) | 2006-12-22 | 2014-06-17 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
| DK2865760T3 (en) | 2008-06-24 | 2018-01-15 | Csl Behring Gmbh | Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life |
| CA2816575C (en) * | 2010-11-05 | 2019-06-11 | Baxter Healthcare S.A. | A new variant of antihemophilic factor viii having increased specific activity |
| SI23610A (sl) | 2011-01-13 | 2012-07-31 | Diagen@d@o@o | Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji |
| KR20140083036A (ko) | 2011-10-18 | 2014-07-03 | 체에스엘 베링 게엠베하 | 인자 ｖｉｉｉ의 생체이용률을 향상시키기 위한 황산화 글리코사미노글리칸의 용도 |
| KR20140083035A (ko) | 2011-10-18 | 2014-07-03 | 체에스엘 베링 게엠베하 | 인자 ｖｉｉｉ의 생체이용률을 증가시키기 위한 황산화 글리코사미노글리칸과 하이알루로니다제의 병용 사용 |
| AU2012318292B2 (en) | 2011-10-18 | 2015-08-20 | Csl Limited | Method for improving the stability of purified Factor VIII after reconstitution |
| PL2814502T3 (pl) | 2012-02-15 | 2018-02-28 | Csl Behring Gmbh | Warianty czynnika von Willebranda mające ulepszone powinowactwo do wiązania czynnika VIII |
| US20150337028A1 (en) * | 2012-09-12 | 2015-11-26 | Centre For Bioseparation Technology-Vit | Double Mutant Coagulation Factor VIII and Methods Thereof |
| KR20150088853A (ko) | 2012-11-29 | 2015-08-03 | 바이엘 헬스케어 엘엘씨 | 활성화 단백질 c에 대한 인간화 모노클로날 항체 및 그의 용도 |
| EP2925351A4 (en) * | 2012-11-29 | 2016-08-24 | Bayer Healthcare Llc | MONOCLONAL ANTIBODIES DIRECTED AGAINST ACTIVATED PROTEIN C (APC) |
| US9914764B2 (en) | 2013-03-15 | 2018-03-13 | Bayer Healthcare, Llc | Variant factor VIII polypeptides and methods of their production and use |
| ES2657291T3 (es) | 2013-04-22 | 2018-03-02 | Csl Ltd. | Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro |
| EP3114138B1 (en) | 2014-03-05 | 2021-11-17 | Pfizer Inc. | Improved muteins of clotting factor viii |
| EP3164150B1 (en) | 2014-07-02 | 2020-11-04 | CSL Behring Lengnau AG | Modified von willebrand factor |
| KR20170125941A (ko) | 2015-03-06 | 2017-11-15 | 체에스엘 베링 리컴비넌트 퍼실리티 아게 | 개선된 반감기를 갖는 변형된 폰 빌레브란트 인자 |
| WO2016142289A1 (en) * | 2015-03-06 | 2016-09-15 | Csl Behring Recombinant Facility Ag | Compounds for improving the half-life of von willebrand factor |
| EP4089109A3 (en) | 2015-05-22 | 2023-03-01 | CSL Behring Lengnau AG | Methods for preparing modified von willebrand factor |
| BR112017023785A2 (pt) | 2015-05-22 | 2018-07-17 | Csl Behring Recombinant Facility Ag | polipeptídeos do fator de von willebrand truncados para tratar hemofilia |
| US11077187B2 (en) | 2015-11-17 | 2021-08-03 | Oklahoma Medical Research Foundation | Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof |
| RU2018128582A (ru) | 2016-01-07 | 2020-02-11 | Цсл Беринг Ленгнау Аг | Мутированный укороченный фактор фон виллебранда |
| DK3400238T3 (da) | 2016-01-07 | 2021-07-26 | CSL Behring Lengnau AG | Muteret von willebrand faktor |
| SG11201903954WA (en) | 2016-11-11 | 2019-05-30 | CSL Behring Lengnau AG | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder |
| US11814421B2 (en) | 2016-11-11 | 2023-11-14 | CSL Behring Lengnau AG | Truncated von Willebrand Factor polypeptides for treating hemophilia |
| CA3115535A1 (en) * | 2018-10-23 | 2020-04-30 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating factor viii function |
| US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
| EP4069269A4 (en) * | 2019-12-06 | 2023-12-27 | The Children's Hospital Of Philadelphia | COMPOSITIONS AND METHODS FOR MODULATING FACTOR VIII FUNCTION |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5214033A (en) | 1983-03-31 | 1993-05-25 | Scripps Clinic & Research Foundation | Factor VIII coagulant polypeptides |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US5045455A (en) | 1984-01-12 | 1991-09-03 | Chiron Corporation | Factor VIII:C cDNA cloning and expression |
| SE8501050D0 (sv) | 1985-03-05 | 1985-03-05 | Kabivitrum Ab | Biologically active fragments of human antihemophilic factor and method for preparation thereof |
| JPH0788399B2 (ja) | 1985-04-12 | 1995-09-27 | ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド | 新規プロコアギュラント蛋白質 |
| US5250421A (en) | 1986-01-03 | 1993-10-05 | Genetics Institute, Inc. | Method for producing factor VIII:C-type proteins |
| WO1987004187A1 (en) | 1986-01-03 | 1987-07-16 | Genetics Institute, Inc. | METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS |
| AT388079B (de) | 1986-04-18 | 1989-04-25 | Helmut Ing Koenig | Backofen |
| US5422260A (en) * | 1986-05-29 | 1995-06-06 | Genetics Institute, Inc. -Legal Affairs | Human factor VIII:c muteins |
| US5451521A (en) * | 1986-05-29 | 1995-09-19 | Genetics Institute, Inc. | Procoagulant proteins |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| CA1331157C (en) | 1987-04-06 | 1994-08-02 | Randal J. Kaufman | Method for producing factor viii:c-type proteins |
| DE3720246A1 (de) | 1987-06-19 | 1988-12-29 | Behringwerke Ag | Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet |
| US5004803A (en) | 1988-11-14 | 1991-04-02 | Genetics Institute, Inc. | Production of procoagulant proteins |
| NZ236094A (en) | 1989-11-17 | 1993-04-28 | Chiron Corp | Recombinant protein complex having human factor viii:c activity |
| US5661008A (en) | 1991-03-15 | 1997-08-26 | Kabi Pharmacia Ab | Recombinant human factor VIII derivatives |
| US5563045A (en) | 1992-11-13 | 1996-10-08 | Genetics Institute, Inc. | Chimeric procoagulant proteins |
| AU6486196A (en) | 1995-07-11 | 1997-02-10 | Chiron Corporation | Novel factor viii:c polypeptide analogs with altered protease sites |
| WO1997003194A1 (en) | 1995-07-11 | 1997-01-30 | Chiron Corporation | Lysine 1689 factor viii:c polypeptide analogs |
| EP0910628B1 (en) | 1996-04-24 | 2006-03-08 | The Regents of The University of Michigan | Inactivation resistant factor viii |
-
1997
- 1997-04-24 EP EP97927596A patent/EP0910628B1/en not_active Expired - Lifetime
- 1997-04-24 EP EP10157809A patent/EP2202242A1/en not_active Withdrawn
- 1997-04-24 PT PT06004484T patent/PT1754718E/pt unknown
- 1997-04-24 CA CA002252896A patent/CA2252896C/en not_active Expired - Fee Related
- 1997-04-24 DE DE69735421T patent/DE69735421T2/de not_active Expired - Lifetime
- 1997-04-24 DK DK06004484.9T patent/DK1754718T3/da active
- 1997-04-24 AT AT97927596T patent/ATE319817T1/de not_active IP Right Cessation
- 1997-04-24 WO PCT/US1997/006563 patent/WO1997040145A1/en not_active Ceased
- 1997-04-24 AU AU32027/97A patent/AU3202797A/en not_active Abandoned
- 1997-04-24 EP EP06004484A patent/EP1754718B1/en not_active Expired - Lifetime
- 1997-04-24 DE DE69740154T patent/DE69740154D1/de not_active Expired - Lifetime
- 1997-04-24 JP JP53821697A patent/JP3987114B2/ja not_active Expired - Fee Related
- 1997-04-24 AT AT06004484T patent/ATE502958T1/de active
-
2001
- 2001-04-11 US US09/819,098 patent/US6838437B2/en not_active Expired - Fee Related
-
2004
- 2004-10-26 US US10/974,534 patent/US7459534B2/en not_active Expired - Fee Related
-
2007
- 2007-04-09 JP JP2007101700A patent/JP4250661B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1754718A2 (en) | 2007-02-21 |
| CA2252896C (en) | 2009-03-10 |
| EP1754718B1 (en) | 2011-03-23 |
| AU3202797A (en) | 1997-11-12 |
| EP0910628A4 (en) | 2001-05-02 |
| DK1754718T3 (da) | 2011-07-18 |
| JP4250661B2 (ja) | 2009-04-08 |
| DE69740154D1 (de) | 2011-05-05 |
| ATE319817T1 (de) | 2006-03-15 |
| US6838437B2 (en) | 2005-01-04 |
| ATE502958T1 (de) | 2011-04-15 |
| EP0910628B1 (en) | 2006-03-08 |
| WO1997040145A1 (en) | 1997-10-30 |
| EP1754718A3 (en) | 2007-05-16 |
| EP2202242A1 (en) | 2010-06-30 |
| JP2000511407A (ja) | 2000-09-05 |
| DE69735421D1 (de) | 2006-05-04 |
| JP3987114B2 (ja) | 2007-10-03 |
| US20020132306A1 (en) | 2002-09-19 |
| US20060014683A1 (en) | 2006-01-19 |
| JP2007228973A (ja) | 2007-09-13 |
| US7459534B2 (en) | 2008-12-02 |
| EP0910628A1 (en) | 1999-04-28 |
| CA2252896A1 (en) | 1997-10-30 |
| DE69735421T2 (de) | 2006-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1754718E (pt) | Factor viii resistente à inactivação | |
| DE69332955T2 (de) | Chimäre prokoagulierende Proteine | |
| AU645539B2 (en) | A recombinant human factor VIII derivative | |
| GEP20033002B (en) | Osteoprotegerin Binding Protein and Receptors | |
| DE69018920D1 (de) | Verwendung von dns-fragmenten, die ein signalpeptid kodieren zur sekretion von reifen proteinen in rekombinanten hefen, expressions-kassetten, transformierte hefen und verfahren zur herstellung dieser proteine. | |
| EP0442961A1 (en) | HYBRID PROCOAGULATING PROTEINS. | |
| EP0731636A4 (en) | APOPTOSIS-MODULATING PROTEINS, DNA-ENCODING, AND METHOD FOR THEIR USE | |
| AU3498189A (en) | Fibronectin binding protein | |
| EP0205475A4 (en) | RECOMBINANT METHOD FOR THE PRODUCTION OF SERINE PROTEASE INHIBITORS, AND DNA SEQUENCES THEREOF. | |
| AU3793493A (en) | Therapeutic domains of von willebrand factor | |
| MX9708426A (es) | Polipeptido hk2 de variante estable. | |
| ATE211390T1 (de) | Überlegende thrombomodulinanaloga zur pharmazeutischen verwendung | |
| EP0665888A4 (en) | ALLERGEN FROM RAYGRASS POLLEN. | |
| EP0576426A4 (enExample) | ||
| MX9806041A (es) | Proteina purificada sr-p70. | |
| ATE190630T1 (de) | Angiotensin-ii typ-1 rezeptor und dessen herstellung | |
| AU5076393A (en) | Proteins which regulate the expression of vertebrate MHC class II genes, DNA sequences encoding them and pharmaceutical compositions | |
| DE60124380D1 (de) | Angiogenese-assoziierte proteine und dafür kodierende nukleinsäure | |
| EP0367641A3 (en) | Lymphokines, dna sequences encoding these lymphokines and pharmaceutical compositions containing these lymphokines | |
| NO921219D0 (no) | Somatostatin reseptor | |
| WO1995018828A1 (en) | Factor viii derivatives |